Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral semaglutide cardiovascular outcomes in high-risk type 2 diabetes
CTR20192079Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Dec 2019
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of semaglutide in type 2 diabetes mellitus (T2DM), cardiac morbidity, chronic kidney disease (CKD), sponsored by Novo Nordisk. Started Dec 2019; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)cardiac morbiditychronic kidney disease (CKD)
Beyond the preview
Go deeper on CTR20192079.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20192079.